NYSE · WRBYHealthcareOphthalmic Goods

Warby Parker financials

$27.47+11.39%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
Revenue$871.9M$771.3M$669.8M$598.1M$540.8M
Gross profit$470.6M$426.8M$365.2M$341.1M$317.7M
Gross margin54.0%55.3%54.5%57.0%58.8%
Operating income-$5.3M-$30.1M-$72.0M-$111.2M-$143.7M
Net income$1.6M-$20.4M-$63.2M-$110.4M-$157.4M
Net margin0.2%−2.6%−9.4%−18.5%−29.1%
Diluted EPS$0.01$-0.17$-0.54$-0.96$-2.21
EBITDA$48.3M$19.5M-$30.5M-$79.1M-$122.1M
Operating cash flow$110.8M$98.7M$61.0M$10.4M-$32.0M
Free cash flow$43.7M$34.7M$7.3M-$49.8M-$80.5M
Diluted shares125.1M120.4M117.4M114.9M71.2M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$286.4M$254.2M$216.9M$208.6M$256.4M
Short-term investments$0.00$0.00$0.00$0.00—
Total debt$0.00$0.00$0.00$0.00$0.00
Total assets$720.9M$676.5M$580.3M$568.7M$440.6M
Total liabilities$353.2M$336.4M$278.5M$282.1M$154.6M
Shareholders' equity$367.7M$340.1M$301.8M$286.6M$286.0M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology